HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA)

Autor: Sergio Amarri, Pietro Lazzeroni, Anna Maria Fulghesu, Maria E. Street, Francesca Cirillo, Gabriele Tridenti, Cecilia Catellani, Chiara Sartori, Cristina Vezzani, Eleonora Madeddu
Rok vydání: 2020
Předmět:
medicine.medical_specialty
Adolescent
endocrine system diseases
Endocrinology
Diabetes and Metabolism
Alpha-Lipoic Acid
chemical and pharmacologic phenomena
030209 endocrinology & metabolism
HMGB1
Young Adult
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Internal medicine
medicine
Humans
Testosterone
Inositol
HMGB1 Protein
Ovarian Reserve
030219 obstetrics & reproductive medicine
Estradiol
Thioctic Acid
biology
business.industry
Polycystic ovary syndrome (PCOS)
Ovary
nutritional and metabolic diseases
Obstetrics and Gynecology
Luteinizing Hormone
medicine.disease
female genital diseases and pregnancy complications
Pathophysiology
Treatment Outcome
chemistry
biology.protein
Drug Therapy
Combination
Female
business
After treatment
Polycystic Ovary Syndrome
Zdroj: Gynecological Endocrinology. 36:588-593
ISSN: 1473-0766
0951-3590
DOI: 10.1080/09513590.2020.1725967
Popis: PCOS treatment should be based on pathophysiology. High-mobility-group-box-1 (HMGB1) was shown to increase in PCOS patients as a consequence of reduced cystic-fibrosis-transmembrane-conductance-regulator (CFTR) expression in the ovary, and was associated with insulin resistance and inflammation, both features of PCOS. Inositols and ALA derivatives could have positive effects on insulin sensitivity, reduce androgens, and improve ovulation rhythm. The aim of this study was to verify changes in HMGB1, in metabolic and endocrine parameters in adolescents with PCOS compared with controls and after treatment with a combination of MYO + ALA. Twenty-three PCOS adolescents and 21 controls matched for age and BMI were enrolled. In all subjects, metabolic and hormonal parameters were assayed. Homeostatic index (HOMA-IR) and the triglyceride/HDL-cholesterol ratio were calculated. Ovarian volumes were evaluated. Patients were treated with MYO + ALA for 6 months. HMGB1 was measured using a specific ELISA assay. HMGB1 was increased in PCOS compared with controls (19.76 ± 5.99 versus 5.65 ± 1.88 ng/ml
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje